Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - September 14, 2022

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to the public of $10.32 per share. All of the shares are to be sold by Edgewise Therapeutics. In addition, Edgewise Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,744,186 shares of its common stock. Before deducting the underwriting discounts and commissions and offering expenses, Edgewise Therapeutics expects to receive total gross proceeds of $120 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about September 16, 2022, subject to satisfaction of customary closing conditions.

J.P. Morgan and SVB Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Edgewise Therapeutics filed a Registration Statement on Form S-3, which was declared effective by the SEC, and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.

When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:

J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: prospectus-eq_fi@jpmchase.com; or

SVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Edgewise Therapeutics will be able to raise capital through the sale of shares of common stock or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the offering, Edgewise Therapeutics and its business can be found under the heading “Risk Factors” in Edgewise Therapeutics’ most recent current, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Edgewise Therapeutics assumes no duty or obligation to update or revise any forward-looking statements for any reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006310/en/

Contacts

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com

Source: Edgewise Therapeutics

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20220913006310/en

Back to news